Fig. 3.

Anti-tumor effects of bi- and trifunctional nanodrugs in the WEHI-164 fibrosarcoma model. Tumor-bearing mice were treated at the indicated times (arrows) after tumor implantation with the indicated doses of iso1Au/TNF (a), iso1Au/IL12 (b) or iso1Au/TNF + IL12 (c) (TNF:IL12 molar ratio, 1:4.5) (i.v.). The indicated doses correspond to immunoreactive IL12, as detected by ELISA, or bioactive TNF, as determined by the L–M cytolytic assay. The tumor volumes are shown (mean ± SE, 4–6 mice per group). *P < 0.05; **P < 0.01 by Mann–Whitney analysis of the area under the curve for each tumor with GraphPad Prism software